TrialPath
Recruiting

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

NCT07140172 · University Hospital, Basel, Switzerland
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery: An International, Randomized Superiority Trial (OPBC-10/ NOAX)
About this study
Despite major morbidity, axillary lymph node dissection (ALND) is standard of care in patients with clinically node positive breast cancer (cN+ BC) who undergo upfront surgery, which is frequently indicated in case of luminal biology. Tailored axillary surgery (TAS) was shown to selectively target positive nodes, thereby removing significantly more nodes than sentinel lymph node biopsy (SLNB), but less nodes than ALND. Therefore, it is currently unclear if TAS in combination with axillary radiotherapy (ART) exposes the axilla to less harm compared to ALND. It is hypothesized that patient's quality of life (QoL) and morbidity can be improved by replacing ALND with the combination of TAS and ART in patients undergoing upfront surgery. The main goal of this trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related QoL and occurrence of lymphedema two years after randomization.
Eligibility criteria
Inclusion Criteria at screening: * Written informed consent according to ICH/GCP regulations prior to any trial specific procedures. * Patients ≥ 18 years of age. * Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer/ International Union Against Cancer (AJCC/UICC) stage II-III (all molecular subtypes allowed). * Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology. * Node-positivity palpable (cN1-3) and confirmed by pathology. * Occult breast cancer is allowed, if biopsy-proven axillary lymphatic metastasis is present. * Eligible for primary ALND or SLN procedure and either: * Newly diagnosed. * Isolated in-breast recurrence or second ipsilateral breast cancer after previous breast conserving surgery and sentinel procedure and at least 3 years disease free and no prior axillary dissection or axillary RT. * Upfront surgery setting. * Most suspicious axillary lymph node clipped. (If clipping is not part of the routine, this should be done after consent of the patient as a study procedure.) * Ability to complete the QoL questionnaires. * WHO performance status 0-2 * Adequate condition for general anesthesia, breast cancer surgery and radiotherapy. * Adult patients (≥18 years of age). * Women of child-bearing potential are using effective contraception (condom, diaphragm, intrauterine device), are not pregnant or lactating and agree not to become pregnant during trial treatment (until end of RT) and thereafter during the time recommended by the guidelines - also for adjuvant systemic therapies. A negative pregnancy test before registration is required for all women of child-bearing potential. * Men agree not to father a child during trial treatment and for 6 months afterward. Exclusion criteria at screening: * Stage IV breast cancer. * Clinical N3c breast cancer without axillary disease (clinical N3a and clinical N3b are allowed). * Clinical N2b breast cancer (clinical N2a is allowed). * Contralateral breast cancer within 3 years. * Prior axillary surgery (except prior sentinel node procedure in case of in-breast recurrence). * Prior regional radiotherapy. * Neoadjuvant treatment with the exception of bridging therapy given for less than 3 months. * History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer. * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. Exclusion criteria at randomization (intraoperatively): * Absence of clip in the specimen radiography. * Palpable disease left behind in the axilla after TAS. * No SLN identified in the axilla.
Study design
Enrollment target: 1060 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-01-01
Estimated completion: 2037-12
Last updated: 2026-10-14
Interventions
Procedure: Axillary lymph node dissection (ALND)Procedure: Axillary radiotherapy (ART)
Primary outcomes
  • • Change in arm-related Quality of Life (QoL) (From baseline to 2 years after randomization)
  • • Occurrence of lymphedema (From baseline to 2 years after randomization)
Sponsor
University Hospital, Basel, Switzerland · other
Contacts & investigators
ContactWalter P. Weber, Prof. Dr. med. · contact · walter.weber@usb.ch · +41 61 328 61 49
ContactOPBC project management team · contact · noax.trial@usb.ch · +41 61 55 65134
InvestigatorWalter P. Weber, Prof. Dr. med. · principal_investigator, Breast Surgery Service, University Hospital Basel
All locations (55)
Walter Reed National Military Medical CenterNot Yet Recruiting
Bethesda, Maryland, United States
Duke University/Duke Cancer CenterNot Yet Recruiting
Durham, North Carolina, United States
Fox Chase Cancer CenterRecruiting
Philadelphia, Pennsylvania, United States
KH DornbirnRecruiting
Dornbirn, Austria
LKH FeldkirchRecruiting
Feldkirch, Austria
MUI - Univ. Klinik f. Frauenheilkunde InnsbruckRecruiting
Innsbruck, Austria
Ordensklinikum LinzRecruiting
Linz, Austria
Medical University Vienna, Department of GynecologyNot Yet Recruiting
Vienna, Austria
Medical University Vienna, Department of SurgeryRecruiting
Vienna, Austria
CIUSSS du Centre Ouest-de-l 'Ile-de-MontréalRecruiting
Montreal, Canada
Breast Centre of Clinical Hospital, RijekaNot Yet Recruiting
Rijeka, Croatia
University Hospital Heidelberg, Women's ClinicRecruiting
Heidelberg, Germany
Brustzentrum Heidelberg Klinik St. Elisabeth GmbHRecruiting
Heidelberg, Germany
Breast Center OsnabrückRecruiting
Osnabrück, Germany
HELIOS Universitätsklinikum WuppertalNot Yet Recruiting
Wuppertal, Germany
"Alexandra" Hospital, AthensNot Yet Recruiting
Athens, Greece
University Hospital of HeraklionNot Yet Recruiting
Heraklion, Greece
University Hospital of LarissaNot Yet Recruiting
Larissa, Greece
Cork University HospitalNot Yet Recruiting
Cork, Ireland
St- Luke's Hospital DublinNot Yet Recruiting
Dublin, Ireland
St. James's Hospital DublinNot Yet Recruiting
Dublin, Ireland
St. Vincent's University HospitalNot Yet Recruiting
Dublin, Ireland
University Hospital GalwayRecruiting
Galway, Ireland
Istituto Oncologico Veneto IRCCSNot Yet Recruiting
Padova, Italy
Policlinico Universitario "Agostino GemelliNot Yet Recruiting
Rome, Italy
Pauls Stradiņš Clinical University HospitalRecruiting
Riga, Latvia
Cantonal Hospital AarauRecruiting
Aarau, Switzerland
Kantonsspital BadenRecruiting
Baden, Switzerland
Breast Surgery Service, University Hospital BaselRecruiting
Basel, Switzerland
University Hospital of Bern (Inselspital)Not Yet Recruiting
Bern, Switzerland
Spital BülachNot Yet Recruiting
Bülach, Switzerland
Clinique des GrangettesRecruiting
Chêne-Bougeries, Switzerland
Graubünden Cantonal HospitalRecruiting
Chur, Switzerland
Spital ThurgauRecruiting
Frauenfeld, Switzerland
Hôpitaux Universitaires de GenèveRecruiting
Geneva, Switzerland
Clinique de GenolierRecruiting
Genolier, Switzerland
Hirslandenklinik St. AnnaRecruiting
Lucerne, Switzerland
Kantonsspital LuzernRecruiting
Lucerne, Switzerland
Centro di Senologia della Svizzera ItalianaRecruiting
Lugano, Switzerland
Ticino Breast CenterRecruiting
Lugano, Switzerland
Hôpital NeuchâteloisRecruiting
Neuchâtel, Switzerland
Bethesda Hospital BaselRecruiting
Pratteln, Switzerland
Kantonsspital St. GallenRecruiting
Sankt Gallen, Switzerland
Tumor-& Brustzentrum Ostschweiz St. GallenRecruiting
Sankt Gallen, Switzerland
Schaffhausen Cantonal HospitalRecruiting
Schaffhausen, Switzerland
Spital LimmattalRecruiting
Schlieren, Switzerland
Hôpital du Valais, Hôpital de SionRecruiting
Sion, Switzerland
Bürgerspital SolothurnNot Yet Recruiting
Solothurn, Switzerland
Kantonsspital WinterthurRecruiting
Winterthur, Switzerland
Spital ZollikerbergRecruiting
Zollikerberg, Switzerland
Brustzentrum Zürich (Seefeld)Recruiting
Zurich, Switzerland
Stadtspital TriemliRecruiting
Zurich, Switzerland
University Hospital ZürichRecruiting
Zurich, Switzerland
Department of General Surgery, Breast Unit, Istanbul Faculty of Medicine, Istanbul UniversityNot Yet Recruiting
Istanbul, Turkey (Türkiye)
Istanbul Bağcılar Training and Research HospitalNot Yet Recruiting
Istanbul, Turkey (Türkiye)
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery · TrialPath